---
title: "Arcutis director Terrie Curran disposes of common shares worth $279,129.66"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297371506.md"
description: "Arcutis Biotherapeutics director Terrie Curran exercised stock options for 38,200 shares on Aug. 27, 2026, and immediately sold them at a weighted average price of $25.03, realizing proceeds worth $279,129.66. Following these transactions, her direct holdings decreased to 23,526 common shares."
datetime: "2026-08-28T21:40:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297371506.md)
  - [en](https://longbridge.com/en/news/297371506.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297371506.md)
generator: "portal-rs"
---

# Arcutis director Terrie Curran disposes of common shares worth $279,129.66

-   Arcutis Biotherapeutics director Terrie Curran exercised stock options on Aug. 27, 2026, acquiring 38,200 common shares at USD 7.51–8.63. \* Curran sold 38,200 common shares the same day at a weighted average price of USD 25.03. \* Directly held common shares fell to 23,526 following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-059444), on August 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ARQT.US](https://longbridge.com/en/quote/ARQT.US.md)

## Related News & Research

- [Arcutis Biotherapeutics Director Howard G. Welgus Reports Disposal of Common Shares Worth $127,325.04](https://longbridge.com/en/news/302327833.md)
- [Cantor Fitzgerald initiates coverage of Arcutis Biotherapeutics with Overweight rating, $48 price target](https://longbridge.com/en/news/301963556.md)
- [AI fever ignites a boom in thematic ETFs as fund managers hunt for their next big hit](https://longbridge.com/en/news/302963080.md)
- [Arcutis EVP, Chief Legal Officer Masaru Matsuda disposes of 3,674 common shares for $91,753.31](https://longbridge.com/en/news/299485014.md)
- [Arcutis says Phase 2 trial shows Zoryve cream 0.05% clears atopic dermatitis in infants ages 3 to under 24 months](https://longbridge.com/en/news/301396737.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**